Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 22;11(3):e006262. doi: 10.1136/jitc-2022-006262

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Target modulation by daratumumab in evaluable prostate tumors and bone marrow as assessed by flow cytometry. Flow cytometric analysis gated on CD45⁺ live cells showing frequency of CD38⁺ cells in (A) CD45⁺ immune cells; (B) CD3⁺ T cells; (C) CD8⁺ T cells; (D) CD4⁺ T cells; (E) CD4⁺CD25⁺FoxP3⁺ Treg cells; (F) CD11b⁺CD14⁺HLA-DR⁺ myeloid cells; (G) CD3-CD19-CD56⁺ NK cells. Daratumumab-treated versus untreated prostate tumors and patient-matched pre-daratumumab and post-daratumumab bone marrow aspirates were assessed. NK, natural killer.